The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Predicting response to ven-aza in newly diagnosed AML solely based on bone marrow smear image data
Jan-Niklas Eckardt, MSc, MHBA, Technical University Dresden, Dresden, Germany, comments on the potential of using bone marrow smear images to predict response to venetoclax plus azacitidine (ven-aza) combination therapy in patients with newly diagnosed acute myeloid leukemia (AML). Dr Eckardt discusses an artificial intelligence (AI) model that is being developed, which can analyze images from bone marrow smear images acquired at initial diagnosis to identify patients who will respond to treatment. In an initial study, the model demonstrated over 80% accuracy and is now being prospectively and externally validated. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
